iiinova — where your digital self keeps evolving

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

That’s a wrap for the day on antibody drug conjugates at the @mitkochinstitute.bsky.social ! Awesome course on these complicated and exciting molecules (and their relatives)! Lots more exciting anti-cancer science to come 💊 #KIsymposium

031

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Michael Seganish closes out the day discussing what happens when an ADC payloads detaches, even when it’s supposed to, and gets into circulation instead of into its target cell. Spoiler alert: toxic side effects @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Puja Sapra brings perspective on the evolution of the ADC field: much learned and much to be done in terms of improving targets, understanding why different ADCs work differently, and deriving novel combos for future use. @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Greg Thurber starts session 3 with perspective on the trajectory of ADCs in the clinic & in research- there's been a steady increase in approved ADC molecules for clinical use since early 2000s! @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Daša Lipovšek expanding today's discussion to include miniprotein radioconjugates, which link target-binding proteins with radioisotopes that can kill cells or be detected with imaging devices. This facilitates greater targeting and functionality. @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Jeremiah Johnson's antibody-bottlebrush conjugates aim to enable loading more drug onto ADCs using hydrophilic sidechain linkers that stabilize more, larger, & combos of payloads. This opens doors to more options for ADC design across more contexts @mitkochinstitute.bsky.social #KIsymposium

011

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Dane Wittrup's lab is innovating ADCs by designing linker-less ADCs, which can enable release of payloads that cells can then take up over time- enabling better and potentially more potent targeting @mitkochinstitute.bsky.social #KIsymposium

021

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Kicking off session 2 is Laurie Boyer, discussing how to visualize how molecules (like ADCs) are traveling into and around cells. Regular light microscopy isn't sufficient and more complicated super-resolution microscopes are expensive and hard to use.

100

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Last in Session 1: Timothy Lowinger discusses targeting immune pathways! STING agonism activates innate immunity, but it's important and difficult to deliver this only to tumor lesions. ADCs can bring the drug directly to the tumor microenvironment @mitkochinstitute.bsky.social #KIsymposium

011

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Alison Betts: With the promise of ADCs comes a need to better understand their mechanisms + toxicities. Quantitative Systems Pharmacology modeling uses applied math to study data from ADC trials, aiding in the design of new & improved versions. @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Next in session 1: Gerold Meinhardt with clinical data on Trastuzumab Deruxtecan, a HER2 ADC with great efficacy for breast cancer patients in a variety of contexts, including patients that have already been treated with other agents @mitkochinstitute.bsky.social #KIsymposium

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Now, Peter Senter discussing challenges and progress in antibody drug conjugates for cancer- tricky in terms of design, potency, toxicity, etc. However, ADCs have already led to huge improvements, such as in Hodgkin's lyphoma and urothelial cancer. #KIsymposium @mitkochinstitute.bsky.social

111

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

First, our keynote speaker @carolynbertozzi.bskyverified.social (Nobel Laureate!) introducing bioorthogonal chemistry: reactions that can occur within a living cell, with all its physiological constraints, without interfering with biology @mitkochinstitute.bsky.social #KISymposium

140

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/06/2025

Live posting today from the @mitkochinstitute.bsky.social annual symposium on Antibody Drug Conjugates #KISymposium. Excited for the amazing lineup of speakers!

041

Reposted by Meaghan McGeary, PhD

Ludwig Cancer Research @ludwigcancer.bsky.social · 11/06/2025

We recently attended the Ludwig @mit.edu retreat and caught up with many of our colleagues there. Here, founding Director, Ludwig Professor and giant of cancer research Robert Weinberg reflects on his scientific fascinations and career. youtu.be/UEDP2_RA6MI #CanSky #OncoSky

youtu.be

Robert Weinberg, Ludwig MIT

YouTube video by Ludwig Cancer Research

061

Reposted by Meaghan McGeary, PhD

MIT Koch Institute @mitkochinstitute.bsky.social · 10/06/2025

“It’s not justifying the research—it’s justifying spending money on the research.” This spring, Koch Institute postdoc Meaghan McGeary took that message to Capitol Hill during AACR Hill Day, urging policymakers to sustain federal funding for cancer research. buff.ly/EgnUNzq

011

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 27/02/2025

Today I visited Capitol Hill with @theaacr.bsky.social and other early-career cancer researchers to advocate for increasing funding to NIH and NCI, and to share the impact of recent measures to cut federal spending on research. It was exciting and empowering, and I learned so much. 🧵

140

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 26/02/2025

Last meeting- grateful for the time in @nadler.house.gov office to discuss what loss of cancer research funding means for NYC and the country @aacr_cancerresearch #FundNIH #AACRontheHill

040

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 26/02/2025

Thanks to @whipkclark.bsky.social office for meeting with us to hear how NIH funding cuts hurt MA innovation + cancer researchers! #FundNIH #AACRontheHill @AACR @Pederfizzo

040

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 26/02/2025

Grateful to @SenSchumer office for hearing our concerns about loss of funding for cancer research #FundNIH @theaacr.bsky.social

030

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 26/02/2025

Thanks to @edmarkey.bsky.social office for our great #AACRonthehill meeting! We are grateful for your support of cancer research funding and look forward to helping support your fight to #fundNIH @pederfizzo.bsky.social

071

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 26/02/2025

Beyond excited to be at Capitol Hill today with @theaacr.bsky.social at Early Career Hill Day, advocating for funding and support for cancer research #fundNIH #AACRonthehill

1110

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 05/02/2025

We are hiring technicians! The Jacks Lab is a fun, exciting, and supportive place to learn and grow as a scientist- come study cancer with us! 🧬🐭 Apply here: careers.peopleclick.com/careerscp/cl...

careers.peopleclick.com

Technical Associate I, Jacks Lab

MIT - Technical Associate I, Jacks Lab - Cambridge MA 02139

041

Meaghan McGeary, PhD @mk-mcg5.bsky.social · 21/12/2024

“The best way to spread Christmas cheer is singing loud for all to hear”🎄 loved being part of the first Jacks Lab carolers- bringing holiday joy to our community and remembering the most important things about the season ❤️🎶

030